


SCARD Pool report for 01-01-2013 to 31-12-2013

| Participants | Doctors | 221 | |
|---------------------|-----------------------------|--------|---------|
| | Patients | 38,855 | |
| | | | |
| Specimens | New lesions | 75,593 | 86.12% |
| | Previously biopsied lesions | 12,185 | 13.88% |
| | Total lesions | 87,778 | 100.00% |

Breakdown of new versus previously biopsied specimens



| Percentage of new lesions tested which were malignant | 63.22% |
|--|--------|
| Percentage of Definitively excised lesions that were malignant | 79.67% |
| Lesions tested to find one melanoma (NNT) | 5.33 |
| Percentage of lesions tested for NMSC which were NMSC | 74.78% |
| Ratio of New BCCs : New Melanomas | 12:1 |

Accuracy

Diagnostic sensitivity

| Melanomas | 69.38% of 1,832 |
|-----------|------------------|
| All NMSC | 94.96% of 45,039 |
| BCCs | 89.61% of 22,727 |
| SCCs | 83.59% of 22,082 |
| | |

Positive predictive value

| Melanomas | 41.58% of 3,057 |
|-----------|------------------|
| All NMSC | 81.31% of 52,599 |
| BCCs | 38.72% of 52,599 |
| SCCs | 68.92% of 26,783 |

Adequacy


Percentage of definitively managed malignant cases where surgical margins were adequate

| BCC | 84.66% of 15,835 |
|---------------------------|------------------|
| IEC/Bowens disease | 90.15% of 8,742 |
| SCC | 87.89% of 5,631 |
| Keratoacanthoma | 90.91% of 836 |
| Melanoma - in situ | 74.35% of 1,154 |
| Melanoma - invasive | 77.86% of 384 |
| Melanoma - invasive > 1mm | 44.26% of 61 |
| Other malignant | 79.17% of 48 |



Lesion Breakdown Histological Diagnosis

| BCC (unspecified type) | 0 | 0% |
|-----------------------------|--------|--------|
| BCC - Superficial | 8,084 | 10.69% |
| BCC - Nodular/Solid | 10,852 | 14.35% |
| BCC - Aggressive | 3,791 | 5.01% |
| IEC/Bowens disease | 13,464 | 17.80% |
| SCC | 7,461 | 9.87% |
| Keratoacanthoma | 1,157 | 1.53% |
| Pinkus Fibroepithelioma | 6 | 0.01% |
| Merkel cell tumour | 9 | 0.01% |
| Other malignant | 80 | 0.11% |
| NMSC Metastasis | 3 | 0.00% |
| Melanoma - in situ | 1,250 | 1.65% |
| Melanoma - invasive | 424 | 0.56% |
| Melanoma - invasive > 1mm | 130 | 0.17% |
| Melanoma - metastasis | 28 | 0.04% |
| MELTUMP | 132 | 0.17% |
| Naevus - other | 4,058 | 5.37% |
| Naevus - dysplastic/Clark | 2,758 | 3.65% |
| Naevus - blue | 252 | 0.33% |
| Naevus - Spitz/Reed | 142 | 0.19% |
| Naevus - Compound | 0 | 0% |
| Solar keratosis | 6,981 | 9.23% |
| Solar lentigo | 932 | 1.23% |
| Seborrhoeic keratosis | 3,580 | 4.73% |
| Lentigo Simplex | 1 | 0.00% |
| Lichenoid keratosis (LPLK) | 1,406 | 1.86% |
| Dermatofibroma | 519 | 0.69% |
| Sebaceous gland hyperplasia | 188 | 0.25% |
| Benign cyst | 1,062 | 1.40% |
| Other benign | 5,169 | 6.83% |
| Histology Pending | 35 | 0.05% |
| | | |





| Procedures | | | |
|-------------------------------|--|---------|--------|
| Definitive Surgical Ma | nagement used to exclude melanoma | | |
| _ | Ellipse | 1,899 | 93.87% |
| | Flap | 45 | 2.22% |
| | Graft - SSG | 2 | 0.10% |
| | Graft - FTSG | 5 | 0.25% |
| | No Closure | 1 | 0.05% |
| | Shave/Saucerisation | 26 | 1.29% |
| | Curettage & Cautery | 12 | 0.59% |
| | Liquid N2 freeze/thaw | 5 | 0.25% |
| | PDT | 0 | 0% |
| | Imiquimod | 0 | 0% |
| | 5 FU cream | 0 | 0% |
| | GP referral | 1 | 0.05% |
| | Specialist referral | 18 | 0.89% |
| | Other | 2 | 0.10% |
| Biopsy used to exclude | e melanoma | | |
| . , | Punch - sample | 614 | 7.74% |
| | Shave - sample | 855 | 10.78% |
| | Incisional | 96 | 1.21% |
| | Punch - removal | 1,616 | 20.37% |
| | Shave - removal | 2,185 | 27.54% |
| | Excisional | 2,528 | 31.87% |
| | Curettage | 32 | 0.40% |
| | Other | 4 | 0.05% |
| Breakdown of definitiv | ve management procedures for malignant con | ditions | |
| | Ellipse | 29,518 | 69.54% |
| | Flap | 3,683 | 8.68% |
| | Graft - SSG | 354 | 0.83% |
| | Graft - FTSG | 694 | 1.63% |
| | No Closure | 140 | 0.33% |
| | Shave/Saucerisation | 593 | 1.40% |
| | Curettage & Cautery | 4,233 | 9.97% |
| | Liquid N2 freeze/thaw | 580 | 1.37% |
| | PDT | 117 | 0.28% |
| | Imiquimod | 473 | 1.11% |
| | 5 FU cream | 544 | 1.28% |
| | GP referral | 65 | 0.15% |
| | Specialist referral | 994 | 2.34% |
| | Other | 159 | 0.37% |
| Breakdown of definitiv | ve management procedures for benign condit | ions | |
| | Ellipse | 4,070 | 74.72% |
| | Flap | 88 | 1.62% |
| | Graft - SSG | 2 | 0.04% |
| | Graft - FTSG | 11 | 0.20% |
| | No Closure | 3 | 0.06% |
| | Shave/Saucerisation | 437 | 8.02% |
| | Liquid N2 freeze/thaw | 274 | 5.03% |
| | 5 FU cream | 64 | 1.17% |
| | GP referral | 5 | 0.09% |
| | Specialist referral | 25 | 0.46% |
| | Other | 80 | 1.47% |
| | | | |



Procedures (continued)


Percentage of procedures/closures that were complex

| Complex Closures | 10.74% of 42,931 |
|--|------------------|
| Complex Closures (inc Curettage & Cautery) | 9.79% of 47,098 |

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

| Nose | 28 | 0.62% of 4,534 |
|---------------|-----|-----------------|
| Lip | 5 | 0.37% of 1,349 |
| Ear | 40 | 1.35% of 2,970 |
| Eyelid | 7 | 0.90% of 782 |
| Other face | 203 | 1.46% of 13,880 |
| Scalp | 49 | 2.07% of 2,362 |
| Neck | 84 | 2.35% of 3,580 |
| Shoulder | 128 | 3.81% of 3,360 |
| Chest | 78 | 1.84% of 4,228 |
| Abdomen | 51 | 5.37% of 949 |
| Genitalia | 1 | 1.27% of 79 |
| Back | 552 | 5.08% of 10,876 |
| Buttock | 7 | 4.29% of 163 |
| Arm | 178 | 4.18% of 4,258 |
| Forearm | 98 | 1.64% of 5,960 |
| Hand Dorsal | 0 | 0% of 3,079 |
| Hand Palmar | 0 | 0% of 29 |
| Finger Dorsal | 1 | 0.08% of 1,263 |
| Finger Nail | 1 | 9.09% of 11 |
| Finger Palmar | 0 | 0% of 14 |
| Thigh | 96 | 4.49% of 2,138 |
| Leg | 208 | 2.34% of 8,900 |
| Foot Dorsal | 12 | 1.80% of 665 |
| Foot Plantar | 2 | 3.33% of 60 |
| Toe Dorsal | 1 | 1.16% of 86 |
| Toe Nail | 1 | 16.67% of 6 |
| Toe Plantar | 1 | 8.33% of 12 |
| Palm Or Sole | 0 | 0% of 0 |
| | | |



Upper Limbs - 15.17%